Materno-fetal microchimerism is a common, life-long chimeric state fi rst established by the exchange ofsmall numbers of cells between the motherand the fetus during pregnancy. This apparently trivial phenomenon is now attracting attention due to its unexpected andprofound implications in the immune system. For example, is the placenta really an immunological barrier? How do we balance the internal environment despite the existence of an immunological non-self? In this review, I will discuss the pros and cons of materno-fetal microchimerismforour immune system (e.g., tolerance, materno-fetal immune disease, tissue regeneration, etc.) and the unanswered, puzzling aspects of microchimerismfrom theimmunological point of view.
A body consisting of cells from 2 or more genetically distinct populations is called a chimera. Since the number of cells in pregnancyrelated chimera is relatively small (about 1 in 1000~10,000), the phenomenonis called "microchimerism" [7] (Figure 1 ). Meanwhile, despite their low frequency among our own cells, all people are considered to be in a microchimeric state, and parous womenare considered to have cells of more than 3diff erent origins: their own cells, their mother's cells, and those of their children [2] .
Why have these cells come under the spotlight in the fi eld of immunology? Th is review will describe recent advances and emerging questions in this fi eld.
How domicrochimeric cells pass through the placenta?
Let us start with how microchimerism occurs. Although the precise timing of cell transfer remains to be clarifi ed [8] , microchimerism is establishedduring pregnancy [9, 10] . A major question is how these maternal and fetal cells migratedfrom one body to the other. During pregnancy, the risk of immunological confl ict (especially an attack by the maternal immune system) is avoided by the placenta, which fi lters various substances including immune cells. However, based on recent reports,the concept of the placenta as an immunological barrier is now being challenged. Th at is, fetal and maternal cells cross the placenta and engraft with each other, resulting in microchimerism [4, 11] .
How do microchimeric cells become accepted by the host's immune system?
How do host immune systems live with these non-self cells? Although the precise mechanism is still under investigation [4, 12, 13] , the condition of the mother's and infant's immune systems seem to aff ect the number of cells that are exchanged. One factoris thesoundness of the immune systems of the mother and the fetus. For example, in infants with severe combined immunodefi ciency disease (SCID), more cells migrate from the mother into the fetus [14] . Similar results were reported in a mouse model. Whenthe mother mouse was immunologically defi cient (RAG -/-), the mother accepted more fetal cells [15] . Th ese fi ndings show that absence of a functional immune system results in the exchange of a greater number of cells compared to when the immune systems are healthy. Another factor that aff ects the degree of microchimerismis the immunological compatibility between the mother and the fetus. Based on reports from Berry et al.,maternofetal major histocompatibility complex (MHC)compatibility seemsto favor acceptance of maternal cells [16] , albeit this trend was not reproduced in a certain mouse model [17] .
Together, these fi ndings suggest that microchimeric cells are not cells that accidentally crossed the placenta, but are proportions of the cellsthat migrated through the placenta and further survived the selective pressure of the host (maternal or fetal) immune system.Th is in turn provides us a new understanding of the placenta: rather than a strictcellular barrier, it can be regarded as a fi lter that allows a certain amount of cells to pass through.
What kinds of cells migrate through the placenta?
Apuzzling aspect of microchimerism is that it can last for decades aft er pregnancy [1] . Some researchers have suggested that selfreproducing, undiff erentiated stem cells might be involved [2, 18] ; these cells are calledpregnancy-associated progenitor cells (PAPCs) [19] . In accordance with this, recent mouse studies revealed that PAPCs can diff erentiate into various cell types including neurons, astrocytes, oligodendrocytes, and macrophage-like cells [5] . PAPCs are expected to reside withincertain stem cell niches to survive long periods, butthe detailsof this hypothesis are still under investigation [20, 21] . Apart from PAPCs,it is already known that immunologically mature maternal cells such as CD4+ and CD8+ cells are also detected in the diseased tissue of certain congenital diseases. Th is dramatizes once again the issue of microchimerism: how canmicrochimeric cells stay calm in host tissues even when they are immunologically functional?
How can non-self microchimeric cells colonize in the host?
Aft er entering the host (mother or fetus), how can these cells colonize without being eliminated by the host immune system? In mice, microchimeric cells reside at an immunologically privileged site, the brain [5] , but cells found in other organs cannot be explained by this idea.In late 2008, Mold et al. [22] published a paper in Science, showing that the fetal immune system is highly tolerance-inducible against alloantigens.Using 18-22 gestational week fetus-derived cells, they showed that the fetal environment is prone to induce regulatory T cells and selective lowreactivity to maternal antigens [22] .In brief, it appears that thehuman fetus isgenetically designed to accept or tolerate microchimeric maternal cells. And what is the situation in the mother? As in the fetus, tolerance also takes place on the maternal side, possibly lasting for long aft er the pregnancy. Th is ideawas supported by an epidemiological study:during bone marrow graft ing, maternal graft s had a lower occurrence of graft -versus-host (GvHD)disease in comparison to paternal graft s [23, 24] . Complementary knowledge further supports the existence of tolerance in the mother. Experimentally reducing regulatory T cells in the circulation of pregnant mice leads to extensive infl ux of maternal immune cells into the fetus, causing lethal rejection of the fetus [25] . Immunological tolerance for each other is indeed induced in the mother and the fetus, supporting the view that tolerance permits the long survival of microchimeric cells.
Are they just leaky cells? Or do these cells have a physiological role?
In the fi eld of obstetrics, microchimerism is drawing attentionas a noninvasive, antenatal diagnostic tool, since the fetal cellscan easily be obtained from maternal peripheral blood [2, 44] . However, this is only an artifi cial role; what are the physiological roles? Recent studies reporting roles in tissue regeneration are accumulating. One case is from a parous woman with hepatitis Cwho achieved remission despite the fact that she had to interrupt treatment. Biopsy examination revealed that her liver contained thousands of XY cells, and these cells were morphologically indistinguishable from hepatocytes [45] . Another case study by Nelson et al. in 2007 reported a spleen from a type I diabetic male patientthat contained XX cellsthat were expressing insulin peptides [39] . Th e patient did not have a history of organ transplantation, suggesting that these cells originated from his mother.
Th ese studies seem to support the regenerative roles of microchimeric cells; however, is it possiblethat these cells were just bystanders that happened to encounterregenerating tissues? Several studies in mice have clearly shown that this is unlikely, and further provided evidence that microchimeric cells are actively accumulating at regenerating tissues [5, 46] . Importantly, experimentally damaged brain regions had 6 times more fetal cells than uninjured regions [5] , and the frequency of fetal cells was up to 10 in 1000, suggesting that these cells are actively involved in tissue regeneration. To put it plainly, mother and fetus each facilitate the health of the other.
Another advantage of materno-fetal microchimerism is thegraftversus-tumor (GvT) eff ect [47] . Supporting evidence includesthe fact that patients with breast cancer are reported to have lower numbers of fetal microchimeric cells (fMCs), and parous women have a lower occurrence of malignant cancer [48, 49] . Th is circumstantial evidence, however, could be due to the changes in hormonal balance associated with pregnancy, and are rather indirect eff ects of microchimerism. Meanwhile, activated haploidentical peripheral blood stem cell transplantation donated by parents or children topatientswith advanced-stage chemotherapy-refractory solid tumors lends support to the idea. Patients who have a higher number of microchimeric cells before PBSC transplantation have longer survival times and better therapeutic response [50] . Th ese studies might indicate the high GvT potential of microchimeric cells, which are immunologically nonself. Further studies are needed to clarify the advantageous roles of microchimeric cells.
Canimmunological confl ictbe caused by microchimerism?
Given that microchimeric cells have a potential to attack cancer cellsin the host, why do they not attack normal cells in the host? Several reports suggest that this indeed occurs in certain conditions.Infants with SCID have a larger number of maternal cells in theirbodies. In fact, about 16% of these infants have severe GvHD-like symptoms in their skin and liver [14] , indicating that maternal cells do have thepotential to attack fetal cells.
Furthermore, autoimmune diseases like scleroderma are associated with larger numbers of fetal microchimeric cells compared to healthy individuals, and accumulating reports are now challenging the understanding of these diseases as fundamentally autoimmune in nature [2, 19] . Th is is also the case in diseasesin children. Some of the infl ammatory diseases such as juvenile dermatomyositis and biliary atresia (BA) are associated with larger numbers of maternal microchimeric cells [32, 38, 51, 52] . BA is a nonhereditary,rare disease (about 1 in 10,000 births) thatis associated with chronic, progressive liver problems. Surprisingly, we have found that the diseased tissue of BA patients had 20 XX cells in 1,000XY fetal cells on average, and this is 10 times higher than that innormal controls. In addition, these XX cells contained a certain amount of CD8+ cells [32] .
Several studies have reported maternally derived immune cells in certain kinds of congenital diseases [32, 51, 52] . Th e biggest issue is whether these cells are playing major roles in the pathogenesis of infant diseases. What makes this issue complicated is that these diseases are basically infl ammatory diseases, which raises the possibility that increased numbers of maternal microchimeric cells are merely secondaryproducts that have been stimulated to proliferate by fetal immune reactions and have nothing to do with pathogenesis. However, important circumstantial evidence refutes this possibility. Th e number of maternal microchimeric cells increases whenthe mother and the fetus have higher MHCcompatibility, and diseases suspected to involve MMc indeed have a higher ratio of MHC-compatiblemother-child pairs [26, 27, 33] . Th ese reports suggest that the diseases suspected to involve MMc indeed have biased genetic combinationsto receive more maternal cells.We have proposed this hypothetical etiopathogenesis as materno-fetal immune disease, at the prospect of integrating the knowledge of rare but similardiseases [32, 53] . However, it has to be noted that no study has yet clarifi ed that MHC compatibility or microchimerism per se is suffi cient to cause these diseases.
Is microchimerism a programmed cell migration to maintain pregnancy?
As describe above, studies reporting the possible eff ects of materno-fetal microchimerism are accumulating (Table 1) .However, are we really sure that these eff ects are not merely byproducts caused by the abnormal conditions of microchimeric cells? In other words, does microchimerism have certain physiological roles? Although the answers remain to be found, reports in obstetrics raise intriguing possibilities. Highly shared MHC between couples positively correlates with higher risk of recurrent pregnancy loss [54, 55, 56] , suggesting that pregnancy tends to producevarious MHC progenies by nature.
Given that MHC compatibility correlates with higher ratio of microchimerism [16] , it would be worth validating the physiological role of microchimerism in maintaining pregnancy.
Emerging questions in immunology
Many questions concerning microchimerism and immunology remain to be clarifi ed (Figure 2) . Aft er all, thegreatest question is whether pregnancy-associated microchimerism is a boon or a bane. For example, there are cases in which pregnancy ameliorates rheumatoid arthritis, and importantly, the degree of amelioration correlates with fetal microchimeric cells [2] . On the other hand, fMCsare proposed to be involved in the etiopathogenesis of scleroderma on the basis of reports that patients with scleroderma have more fMCs [2] . One reasonable interpretation of these contradictory fi ndings would be that microchimerism could act as both a boon and a bane, depending on the situation, just as our immune system does. Consequently, how is this watershed determined? Why are some people affl icted with various troubles caused by microchimerism, even though all of us have microchimeric cells in our body? Going further, even among people with negative eff ects, such as GvHD-like infl ammation, why is this infl ammation restricted to certain organs or tissues? Further studies, especially with well-controlled animal experiments, would provide important clues to these questions. Systemic lupus erythematosus [27, 28] Multiple sclerosis [2] Primary biliary cirrhosis [29] Sjogren syndrome [30, 31] Biliary atresia [32, 33] Grave disease [34] Hashimoto thyroiditis [35] Juvenile dermatomyositis [36] Fetal loss [37] Neonatal lupus congenital heart block [38] Beta cell regeneration in type I diabetes [39] Rheumatoid arthritis [40, 41] Prevention of breast cancer [42] Tolerance in hematopoietic stem cell transplantation [43] 
